Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776855 | 0.82 | DPP4 (0.45) | MEN1KMT2ACACNA1BDPP4DPP7 | |
| Hydrochloric Acid SCHEMBL2774352 | 0.81 | DPP4 (0.44) | MEN1KMT2ACACNA1BDPP4DPP7 | |
| SCHEMBL6526892 | 0.79 | HSD11B1 (0.52) | — | |
| SCHEMBL6524790 | 0.78 | NAMPT (0.44) | KMT2AHRH3 | |
| SCHEMBL6521562 | 0.78 | DPP4 (0.38) | MEN1KMT2ADPP4DPP7DPP8 | |
| SCHEMBL6518854 | 0.78 | NAMPT (0.44) | KMT2AHRH3 | |
| SCHEMBL2777112 | 0.78 | CCR1 (0.52) | KMT2ACACNA1BCCR1HRH3 | |
| SCHEMBL6525446 | 0.78 | HTR2A (0.42) | KMT2ADPP4DPP7DPP8CCR1 | |
| SCHEMBL6522437 | 0.77 | DPP4 (0.37) | MEN1KMT2ADPP4DPP7DPP8 | |
| SCHEMBL6525292 | 0.77 | PTGDR2 (0.40) | DPP4DPP7CCR1DPP9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | MEN1 1623/4885KMT2A 291/4885CACNA1B 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.